CORDIS
EU research results

CORDIS

English EN

Genome, Environment, Microbiome & Metabolome in Autism: an integrated multi-omic systems biology approach to identify biomarkers for personalized treatment and primary prevention of Autism Spectr

Project information

Grant agreement ID: 825033

Status

Ongoing project

  • Start date

    1 January 2019

  • End date

    31 December 2023

Funded under:

H2020-EU.3.1.2.

  • Overall budget:

    € 14 225 757,50

  • EU contribution

    € 14 225 757,50

Coordinated by:

FONDAZIONE EBRIS

Italy

Objective

GEMMA will be the first project to combine a multi-omic approach with robust environmental data to exploit the analysis of the composition and function of the microbiome for personalized treatment and, ultimately, disease interception in infants at risk of Autistic Spectrum Disorders (ASD) .
The project will provide solid mechanistic evidence of the disease onset and progression in relation to dynamic changes in abnormal gut microbiota causing epigenetic modifications controlling gut barrier and immune functions, based on the in-depth evaluation of 600 infants at risk observed from birth and followed over time. These data will be integrated with pre-clinical studies to mechanistically link human microbiota composition/function with clinical outcome through humanized murine models transplanted with stools obtained from the ASD proband patient of recruited families.
The project will support novel personalized prediction (personalized treatment) and disease interception (prevention) approaches that attempt to modulate gut microbiota to re-establish/maintain immune homeostasis. The biomarkers identified in this project will contribute to a better understanding of the pathogenesis of ASD in at-risk children and the possibility to manipulate the microbiota through pre/pro/symbiotic administration for prevention and treatment, a complete paradigm shift in ASD pathogenesis and early intervention.
The identification of specific ASD metabolic phenotypes will further aid to define biomarkers that can be used as diagnostic tools and patient stratification models for other conditions in which the interplay between genome, microbiome and metabolic profile has been suspected or proved.
Finally, the project will collect biospecimens from a cohort of 600 infants as risk of ASD observed from birth, generating a unique biobank of 16,000+ blood, stool, urine and saliva samples prospectively collected that can be exploited in future multiomic studies.

Coordinator

FONDAZIONE EBRIS

Address

Via De Renzi 1
84125 Salerno

Italy

Activity type

Research Organisations

EU Contribution

€ 2 035 531,25

Participants (16)

NUTRICIA RESEARCH BV

Netherlands

EU Contribution

€ 812 423,75

MEDINOK SPA

Italy

EU Contribution

€ 549 375

BIO MODELING SYSTEMS OU BMSYSTEMS

France

EU Contribution

€ 548 125

EUFORMATICS OY

Finland

EU Contribution

€ 728 437,50

THEOREO SRL

Italy

EU Contribution

€ 426 250

NATIONAL UNIVERSITY OF IRELAND GALWAY

Ireland

EU Contribution

€ 1 663 750

AZIENDA SANITARIA LOCALE SALERNO

Italy

EU Contribution

€ 1 133 375

THE GENERAL HOSPITAL CORPORATION

United States

EU Contribution

€ 1 256 468,75

CONSIGLIO NAZIONALE DELLE RICERCHE

Italy

EU Contribution

€ 544 375

INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT

France

EU Contribution

€ 1 060 617,50

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France

EU Contribution

€ 447 762,50

UNIVERSITEIT UTRECHT

Netherlands

EU Contribution

€ 881 116,25

TAMPEREEN YLIOPISTO

Finland

TAMPEREEN KORKEAKOULUSAATIO SR

Finland

EU Contribution

€ 558 125

IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE

United Kingdom

EU Contribution

€ 832 812,50

JOHNS HOPKINS UNIVERSITY

United States

EU Contribution

€ 747 212,50

Project information

Grant agreement ID: 825033

Status

Ongoing project

  • Start date

    1 January 2019

  • End date

    31 December 2023

Funded under:

H2020-EU.3.1.2.

  • Overall budget:

    € 14 225 757,50

  • EU contribution

    € 14 225 757,50

Coordinated by:

FONDAZIONE EBRIS

Italy